Skip to main content
. Author manuscript; available in PMC: 2014 Sep 22.
Published in final edited form as: Haemophilia. 2012 Sep;18(0 6):1–13. doi: 10.1111/j.1365-2516.2012.02925.x

Table 2.

Primary indication for prophylaxis*.

Prospective Retrospective Total
Site N (%) N (%) N (%)
Epistaxis 4 (66.7) 8 (22.9) 12 (29.3)
GI bleeding 1 (16.7) 7 (20.0) 8 (19.5)
Joint bleeding 1 (16.7) 9 (25.7) 10 (24.4)
Menorrhagia 0 (0.0) 4 (11.4) 4 (9.8)
Other 0 (0.0) 4 (11.4) 4 (9.8)
Mixed 0 (0.0) 3 (8.6) 3 (7.3)
Total 6 (100.0) 35 (100.0) 41 (100.0)
*

Defined as the most severe symptom, or the source of the most significant morbidity.